Camille Ragin, associate director of DEI at Fox Chase Cancer Center, was appointed chair of the Minorities in Cancer Research Council for the American Association for Cancer Research at the AACR annual meeting.
Preclinical data on a development candidate, NTX-452, a novel Werner syndrome helicase inhibitor, was presented at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, by Nimbus Therapeutics.
